GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Enlivex Therapeutics ENLV · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.37

+7.87%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

$1.24bn

FY2016FY2025

Free cash flow

−$10.5m

FY2016FY2025

Shareholders' equity

$1.93bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−$331,999—————————
Research and development$8.9m$10.6m$19.2m$18.7m$12.9m$6.1m$5.7m$4.3m$2.5m$8.9m
Operating income−$15.0m−$15.9m−$25.2m−$25.8m−$19.3m−$9.8m−$8.6m−$5.3m−$6.0m−$15.9m
Net income$1.24bn−$15.0m−$29.1m−$31.1m−$14.5m−$11.8m−$9.4m−$4.2m−$5.9m−$16.0m
Diluted earnings per share6,153.03-164.63-1.56-1.69-0.79-0.88-0.94-8.78-14.23-9,424.71

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.33bn$27.7m$36.8m$67.6m$95.1m$40.4m$17.6m$11.0m$3.6m$10.6m
Cash and short-term investments$5.9m$23.5m$27.3m$48.1m$84.1m$35.7m$12.0m$9.8m$3.5m$6.9m
Total liabilities$392.1m$4.1m$6.7m$10.8m$10.1m$4.9m$6.3m$1.3m$460,000$1.9m
Debt$640,999$534,000$1.0m$653,000$6.0m$203,000$123,000———
Shareholders' equity$1.93bn$23.6m$30.1m$56.8m$85.0m$35.5m$11.3m$9.7m$3.2m$8.7m
Shares outstanding0m0m19m18m18m13m10m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$10.4m−$13.0m−$23.5m−$24.0m−$17.5m−$11.0m−$7.0m−$3.2m−$6.4m−$15.5m
Capital spending−$68,000−$103,000−$236,000−$8.1m−$1.6m−$1.0m−$193,000−$461,000−$2,000−$18,000
Free cash flow−$10.5m−$13.1m−$23.8m−$32.1m−$19.2m−$12.0m−$7.2m−$3.6m−$6.4m−$15.5m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Gross profit−$76,000−$81,000——————
Operating income−$5.9m−$2.6m−$3.1m−$3.5m−$5.6m−$3.1m−$3.0m−$4.2m
Net income$1.24bn−$2.2m−$1.9m−$3.5m−$5.2m−$2.6m−$3.1m−$4.1m
Diluted earnings per share6,190.50-10.98-9.30-17.19-56.75-28.53-33.95-45.39
Cash from operations−$2.0m−$2.0m−$1.0m−$4.0m−$4.0m−$2.0m−$1.0m−$4.0m
Total assets$2.33bn$20.9m$22.6m$24.0m$27.7m$29.8m$31.9m$31.0m
Cash and short-term investments$5.9m$18.3m$19.5m$20.6m$23.5m$24.5m$25.9m$23.4m
Debt$258,000$550,000$264,000$239,000$235,000$346,000$336,000$341,000
Shareholders' equity$1.93bn$17.5m$19.1m$20.6m$23.6m$26.6m$28.6m$26.9m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-16.5%8.9%-0.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings0.0-0.9-99.0-133.6-453.1-549.8-513.4-22.8-41.5-0.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-31%64%-59%-39%-42%11%132%-62%-54%-72%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 16-to-1 reverse split · 27 Oct 2026
  • 15-to-1 reverse split · 9 Jul 2026
  • 1-to-1 reverse split · 26 Mar 2019
  • 8-to-1 reverse split · 6 Mar 2019
  • 5-to-1 reverse split · 25 Sept 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.